Overview

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
Phase:
Phase 2
Details
Lead Sponsor:
OBI Pharma, Inc
Treatments:
Cyclophosphamide